{"product_id":"mca-scientific-events-4th-congress-on-congenital-cytomegalovirus-2025","title":"MCA Scientific Events 4th Congress on Congenital Cytomegalovirus 2025","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: Obstetricians, Gynecologists, Pediatricians, Neonatologists, Infectious Disease Specialists, Virologists, Audiologists, and Immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003cp\u003eTo explore and evaluate screening strategies for CMV in pregnancy across different countries.\u003c\/p\u003e\n\u003cp\u003eTo analyze the complexities and implementation of serological assays for maternal CMV non-primary infections.\u003c\/p\u003e\n\u003cp\u003eTo understand the role of prenatal diagnosis tools, including NIPT, invasive prenatal diagnosis, and digital PCR.\u003c\/p\u003e\n\u003cp\u003eTo discuss the current and future impacts of congenital CMV on children, including inner ear development, neurological disorders, and autism spectrum links.\u003c\/p\u003e\n\u003cp\u003eTo assess the characteristics and progression of hearing loss in children with congenital CMV and debate the efficacy of antiviral treatments.\u003c\/p\u003e\n\u003cp\u003eTo examine the progress and future prospects of realizing a vaccine for the prevention of congenital CMV.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThis congress is designed for healthcare professionals, researchers, and specialists dedicated to the study, diagnosis, and treatment of congenital Cytomegalovirus (cCMV) from the prenatal stage through infancy.\u003c\/p\u003e\n\u003cp\u003eBest for Obstetricians, Gynecologists, Pediatricians, Neonatologists, Infectious Disease Specialists, Virologists, Audiologists, and Immunologists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eThursday, 20 November 2025\u003c\/p\u003e\n\u003cp\u003eOral Communication: Outcome of primary CMV infection in pregnancy in Italy: data from a large multicentric cohort before and after the introduction of valacyclovir in the clinical practice at country level (Lorenzo Zammarchi, Italy)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Congenital Cytomegalovirus Infection in Children Born to Mothers with Primary CMV Infection Treated with Valaciclovir: Analysis of the Multi-center MEGAL-ITALI Study (Elisabetta Venturini, Italy)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Implementation of a national system for reporting and monitoring primary maternal CMV infections in France, in response to the HAS recommendations (Sophie Alain, France)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Occurrence of situations in which early CMV screening serology (\u0026lt;14 weeks of gestation) poses interpretative challenges (Christelle Vauloup-Fellous, France)\u003c\/p\u003e\n\u003cp\u003eOral Communication: CMV-Scan: a highly sensitive serological assay to detect maternal CMV non-primary infection (Ariane Larouche, Canada)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Reduction of voluntary termination of pregnancy in pregnant women with primary Cytomegalovirus infections treated with valaciclovir (Alice Bonetti, Italy)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Beyond the Tip of the Iceberg: The Clinical Impact of Maternal Non-Primary CMV Infection ICCG- Israel Congenital CMV Group (Goni Peleg, Israel)\u003c\/p\u003e\n\u003cp\u003eNIPT for CMV in pregnancy (Brigitte Faas, The Netherlands)\u003c\/p\u003e\n\u003cp\u003eInvasive prenatal diagnosis (Nicolas Bourgon, France)\u003c\/p\u003e\n\u003cp\u003eIs there more for serology to say? (Alfred Bissinger, Germany (online))\u003c\/p\u003e\n\u003cp\u003eSecondary prevention, an international registry (Christros Chatzakis, United Kingdom)\u003c\/p\u003e\n\u003cp\u003eBeyond Real-Time PCR: diagnostic accuracy of Digital PCR in the Pre-natal Diagnosis of Congenital CMV Infection (Liliana Gabrielli, Italy)\u003c\/p\u003e\n\u003cp\u003eHigh-Dose Valacyclovir in Primary Cytomegalovirus Infection During Pregnancy: Effects on Immune Modulation and Maternal Serologic Response (Silvio Tartaglia, Italy)\u003c\/p\u003e\n\u003cp\u003eSuccessful prevention of fetal CMV infection by valacyclovir and the interval between maternal infection and treatment initiation, a retrospective study (Jacob Amir, Israel)\u003c\/p\u003e\n\u003cp\u003eEvaluation of MyCMV: A Tool to Enhance the Diagnosis of Cytomegalovirus Infection During Pregnancy (Jacques Fourgeaud, France)\u003c\/p\u003e\n\u003cp\u003eDiscussion\u003c\/p\u003e\n\u003cp\u003eHow to combine ultrasound and MRI? (Yves Ville, France)\u003c\/p\u003e\n\u003cp\u003eBiology of an infected fetus for best and for worse (Anna Gonce, Spain)\u003c\/p\u003e\n\u003cp\u003ePharmacology of antiviral drugs in pregnancy (Valentine Faure-Bardon, France)\u003c\/p\u003e\n\u003cp\u003eInhibitory effect of antivirals on CMV infection in human stem cell-derived neural systems (Renata Vieira De Sa, The Netherlands)\u003c\/p\u003e\n\u003cp\u003eRate of post-amniocentesis transmission in pregnant women with primary cytomegalovirus infection treated with valaciclovir (Piera d’Angelo, Italy)\u003c\/p\u003e\n\u003cp\u003eCongenital cytomegalovirus causes increased expression of neutrophil granule genes and suppression of innate immune response genes (Helen Payne, United Kingdom)\u003c\/p\u003e\n\u003cp\u003eFriday, 21 November 2025\u003c\/p\u003e\n\u003cp\u003eImpact of CMV on the Inner Ear – Looking through the Developmental Lens (Sharon Cushing, Canada)\u003c\/p\u003e\n\u003cp\u003eRedefining the “Asymptomatic” Child in the Emerging Era of Universal cCMV Screening (Mark Schleiss, United States)\u003c\/p\u003e\n\u003cp\u003eThe link between cCMV and the autistic spectrum? (Marianne Leruez Ville \u0026amp; David Grévent, France)\u003c\/p\u003e\n\u003cp\u003eHow Close Are We? Prospects and Predicaments in Realizing the Goal of Licensing a Vaccine for Prevention of Congenital CMV (Mark Schleiss, United States)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Beyond Hearing and Vision: Pilot Data on Olfactory Function in Congenital Cytomegalovirus (Serena Salomè, Italy)\u003c\/p\u003e\n\u003cp\u003eOral Communication: cCMV infection and risk of autism spectrum and other neurodevelopmental disorders in a large patient population in Northern California (Tara Greenhow, United States)\u003c\/p\u003e\n\u003cp\u003eOral Communication: Educational attainment, absenteeism, and special educational needs outcomes in school children up to age 10\/11 with congenital cytomegalovirus (cCMV): A population-based cohort study using linked education and hospital data from England (Ayana Cant, United Kingdom)\u003c\/p\u003e\n\u003cp\u003eCharacteristics of Progression in Hearing Loss in Children with cCMV (Sharon Cushing, Canada)\u003c\/p\u003e\n\u003cp\u003eAn Enzymatic Assay for Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus (Willow Chernoske, United States)\u003c\/p\u003e\n\u003cp\u003eCMV-specific IFN-γ responses post QuantiFERON CMV test at birth correlate with symptoms at birth and long-term outcome in infants with congenital cytomegalovirus infection (Vana Papaevangelo, Greece)\u003c\/p\u003e\n\u003cp\u003ePRO – Efraim Bilavsky, Israel\u003c\/p\u003e\n\u003cp\u003eCONS – Ann Vossen, Belgium\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405822578884,"sku":null,"price":149.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/MCA-Scientific-Events-4th-Congress-on-Congenital-Cytomegalovirus-2025.jpg?v=1784216680","url":"https:\/\/medicalcoursespro.com\/products\/mca-scientific-events-4th-congress-on-congenital-cytomegalovirus-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}